Ligand validation:4NKV

AER: Abiraterone

AER is a Ligand Of Interest in 4NKV designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4NKV_AER_A_601	41%	1%	0.229	0.947	3.83	4.04	16	24	0	0	100%	1
4NKV_AER_B_601	40%	1%	0.216	0.926	3.45	4.55	14	30	3	0	100%	1
4NKV_AER_C_601	28%	1%	0.269	0.926	3.62	4.29	13	23	0	0	100%	1
4NKV_AER_D_601	19%	1%	0.267	0.865	3.89	4.33	17	26	2	0	100%	1
6WR1_AER_A_601	73%	1%	0.107	0.935	5.1	2.51	15	17	0	0	100%	1
3RUK_AER_A_601	72%	7%	0.147	0.973	2.26	2.59	3	14	3	0	100%	1
4R1Z_AER_A_601	95%	7%	0.077	0.979	2.46	2.34	3	11	3	0	100%	1
6B82_AER_A_602	60%	7%	0.19	0.978	2.28	2.51	1	9	2	0	100%	1
4R20_AER_A_602	59%	7%	0.189	0.974	2.25	2.55	2	16	4	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.